Welcome to BC PharmaCare's public survey of drugs being reviewed for coverage. This survey is for vanzacaftor, tezacaftor, deutivacaftor (Alyftrek) for the treatment of cystic fibrosis (CF) in people aged 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.